Literature DB >> 26158574

Risk of Infection with Chlamydia trachomatis from Migrants to Communities Undergoing Mass Drug Administration for Trachoma Control.

Sheila K West1, Beatriz E Munoz, Harran Mkocha, Charlotte Gaydos, Thomas Quinn.   

Abstract

PURPOSE: To determine the risk of infection with Chlamydia trachomatis in children who are migrants to communities who are undergoing mass drug administration (MDA), and if their neighborhoods have higher rates of infection over time.
METHODS: In four communities in Kongwa, Tanzania, all children were enrolled in a longitudinal study of infection and trachoma. New children were identified at census updates as having not been in the community at the previous census. Within communities, neighborhoods were defined as spatially close groups of households, or "balozi". All children in the communities were invited to be examined for trachoma, and have ocular swabs taken for evidence of infection. Trachoma was graded using the World Health Organization simplified grading scheme, and swabs were processed using Amplicor.
RESULTS: Children who were migrants were more likely to be infected and to have trachoma than children who were resident in the community, which was significant by the time of the survey following the third year of MDA (odds ratio, OR, 2.49, 95% confidence interval, CI, 1.03-6.05). The neighborhoods where newcomers resided were more likely to have infection a year later than neighborhoods with no migrants, which was most pronounced following the third year of MDA (OR 2.86, 95% CI 1.07-7.65).
CONCLUSION: Migrants to communities may be an important source of re-emergent infection, especially as MDA lowers infection among residents. Highly migrant populations may need a special surveillance and treatment program to avoid slowing progress in communities under MDA.

Entities:  

Keywords:  Ocular Chlamydia trachomatis; Tanzania; population; prospective study; trachoma

Mesh:

Substances:

Year:  2015        PMID: 26158574      PMCID: PMC4774537          DOI: 10.3109/09286586.2015.1010687

Source DB:  PubMed          Journal:  Ophthalmic Epidemiol        ISSN: 0928-6586            Impact factor:   1.648


  13 in total

1.  Active trachoma and ocular Chlamydia trachomatis infection in two Gambian regions: on course for elimination by 2020?

Authors:  Emma M Harding-Esch; Tansy Edwards; Ansumana Sillah; Isatou Sarr; Chrissy H Roberts; Paul Snell; Esther Aryee; Sandra Molina; Martin J Holland; David C W Mabey; Robin L Bailey
Journal:  PLoS Negl Trop Dis       Date:  2009-12-22

2.  Do infants increase the risk of re-emergent infection in households after mass drug administration for trachoma?

Authors:  Sheila K West; Dianne Stare; Harran Mkocha; Beatriz Munoz; Charlotte Gaydos; Thomas C Quinn
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-07-29       Impact factor: 4.799

3.  Mass treatment with single-dose azithromycin for trachoma.

Authors:  Anthony W Solomon; Martin J Holland; Neal D E Alexander; Patrick A Massae; Aura Aguirre; Angels Natividad-Sancho; Sandra Molina; Salesia Safari; John F Shao; Paul Courtright; Rosanna W Peeling; Sheila K West; Robin L Bailey; Allen Foster; David C W Mabey
Journal:  N Engl J Med       Date:  2004-11-04       Impact factor: 91.245

4.  Spatial clustering of ocular chlamydial infection over time following treatment, among households in a village in Tanzania.

Authors:  Aimee Teo Broman; Kenny Shum; Beatriz Munoz; Donald D Duncan; Sheila K West
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-01       Impact factor: 4.799

5.  Travel and implications for the elimination of trachoma in ethiopia.

Authors:  Neelima A Shah; Jenafir House; Takele Lakew; Wondu Alemayehu; Colleen Halfpenny; Kevin C Hong; Jeremy D Keenan; Travis C Porco; John P Whitcher; Thomas M Lietman; Bruce D Gaynor
Journal:  Ophthalmic Epidemiol       Date:  2010-03       Impact factor: 1.648

6.  Azithromycin in control of trachoma.

Authors:  J Schachter; S K West; D Mabey; C R Dawson; L Bobo; R Bailey; S Vitale; T C Quinn; A Sheta; S Sallam; H Mkocha; D Mabey; H Faal
Journal:  Lancet       Date:  1999-08-21       Impact factor: 79.321

7.  Strategies for control of trachoma: observational study with quantitative PCR.

Authors:  Anthony W Solomon; Martin J Holland; Matthew J Burton; Sheila K West; Neal D E Alexander; Aura Aguirre; Patrick A Massae; Harran Mkocha; Beatriz Muñoz; Gordon J Johnson; Rosanna W Peeling; Robin L Bailey; Allen Foster; David C W Mabey
Journal:  Lancet       Date:  2003-07-19       Impact factor: 79.321

Review 8.  Trachoma: global magnitude of a preventable cause of blindness.

Authors:  S P Mariotti; D Pascolini; J Rose-Nussbaumer
Journal:  Br J Ophthalmol       Date:  2008-12-19       Impact factor: 4.638

9.  Mass treatment and the effect on the load of Chlamydia trachomatis infection in a trachoma-hyperendemic community.

Authors:  Emily S West; Beatriz Munoz; Harran Mkocha; Martin J Holland; Aura Aguirre; Anthony W Solomon; Robin Bailey; Allen Foster; David Mabey; Sheila K West
Journal:  Invest Ophthalmol Vis Sci       Date:  2005-01       Impact factor: 4.799

10.  Re-emergence of Chlamydia trachomatis infection after mass antibiotic treatment of a trachoma-endemic Gambian community: a longitudinal study.

Authors:  Matthew J Burton; Martin J Holland; Pateh Makalo; Esther A N Aryee; Neal D E Alexander; Ansumana Sillah; Hannah Faal; Sheila K West; Allen Foster; Gordon J Johnson; David C W Mabey; Robin L Bailey
Journal:  Lancet       Date:  2005 Apr 9-15       Impact factor: 79.321

View more
  8 in total

1.  Surveillance and Azithromycin Treatment for Newcomers and Travelers Evaluation (ASANTE) Trial: Design and Baseline Characteristics.

Authors:  Ann-Margret Ervin; Harran Mkocha; Beatriz Munoz; Kurt Dreger; Laura Dize; Charlotte Gaydos; Thomas C Quinn; Sheila K West
Journal:  Ophthalmic Epidemiol       Date:  2016-11-07       Impact factor: 1.648

Review 2.  Trachoma: Past, present and future.

Authors:  Mehrdad Mohammadpour; Mojtaba Abrishami; Ahmad Masoumi; Hassan Hashemi
Journal:  J Curr Ophthalmol       Date:  2016-09-19

3.  Treating village newcomers and travelers for trachoma: Results from ASANTE cluster randomized trial.

Authors:  Sheila K West; Beatriz Munoz; Harran Mkocha; Laura Dize; Charlotte A Gaydos; Bonnie Swenor; Ann-Margret Ervin; Thomas C Quinn
Journal:  PLoS One       Date:  2017-06-29       Impact factor: 3.240

Review 4.  The Relationship between Active Trachoma and Ocular Chlamydia trachomatis Infection before and after Mass Antibiotic Treatment.

Authors:  Athumani M Ramadhani; Tamsyn Derrick; David Macleod; Martin J Holland; Matthew J Burton
Journal:  PLoS Negl Trop Dis       Date:  2016-10-26

5.  Trachoma prevalence remains below threshold in five districts after stopping mass drug administration: results of five surveillance surveys within a hyperendemic setting in Amhara, Ethiopia.

Authors:  Scott D Nash; Aisha E P Stewart; Tigist Astale; Eshetu Sata; Mulat Zerihun; Demelash Gessese; Berhanu Melak; Gedefaw Ayenew; Zebene Ayele; Belay Bayissasse; Melsew Chanyalew; Zerihun Tadesse; E Kelly Callahan
Journal:  Trans R Soc Trop Med Hyg       Date:  2018-12-01       Impact factor: 2.184

6.  Ocular immune responses, Chlamydia trachomatis infection and clinical signs of trachoma before and after azithromycin mass drug administration in a treatment naïve trachoma-endemic Tanzanian community.

Authors:  Athumani M Ramadhani; Tamsyn Derrick; David Macleod; Patrick Massae; Aiweda Malisa; Kelvin Mbuya; Tara Mtuy; William Makupa; Chrissy H Roberts; Robin L Bailey; David C W Mabey; Martin J Holland; Matthew J Burton
Journal:  PLoS Negl Trop Dis       Date:  2019-07-15

7.  Leaving no one behind: targeting mobile and migrant populations with health interventions for disease elimination-a descriptive systematic review.

Authors:  Molly W Adams; Elizabeth G Sutherland; Erin L Eckert; Khalida Saalim; Richard Reithinger
Journal:  BMC Med       Date:  2022-05-09       Impact factor: 11.150

8.  Global Elimination of Trachoma by 2020: A Work in Progress.

Authors:  Caleb Mpyet; Amir Bedri Kello; Anthony W Solomon
Journal:  Ophthalmic Epidemiol       Date:  2015       Impact factor: 1.648

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.